表阿霉素和阿霉素对原代乳腺癌的体外敏感性研究

目的 了解表阿霉素和阿霉素在体外对乳腺癌、癌旁组织和正常乳腺组织的杀伤作用。方法 取得不同患者的乳腺癌、癌旁和正常乳腺组织标本，采用胶原酶消化法获取乳腺原代细胞，应用原代体外培养和MTT法检测化疗药物在不同浓度下对乳腺原代细胞的杀伤率。结果 在1倍PPC（血药浓度）时表阿霉素对乳腺癌原代细胞的体外肿瘤杀伤作用强于阿霉素（P〈0．01）；对正常的乳腺原代细胞，表阿霉素和阿霉素的体外杀伤作用明显下降（P〈0．01），而且表阿霉素弱于阿霉素（P〈0．01）。结论 对于原发乳腺癌患者，表阿霉素不但治疗效果优于阿霉素，而且对肿瘤组织具有更高的选择性，可以作为乳腺癌治疗的一线药物。

Study on Effect of Epirubicin and Doxorubicin with Primary Mammary Cancer in Vitro.

Objective To kown the kill effect of epirubicin and doxorubicin with mammary cancer tissue, peritumor tissue and normal mammary tissue in vitro. Methods To receive mammary cancer tissue, peritumor tissue and normal mammary tissue from diverse patients by surgery, then to obtain different kinds of primary mammary epithelial cells by collagenase, the kill effect of chemotherapy drug with primary mammary epithelial cells was measured by culture in vitro and MTT. Results In vitro, the kill effect of epirubicin with primary mammary cancer cell is better than doxorubicin. The normal mammary epithelial cells is hyposensitive with epirubicin and doxorubicin; Furthermore the kill effect of epirubicin is weaker than doxorubicin. Conclusions As first - line chemotherapy drug of mammary cancer, epirubicin has better antitamor effect than doxorubicin, and it has better selective with tumor tissue.